Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

312 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
NCCN Guidelines Insights: Ovarian Cancer, Version 1.2019.
Armstrong DK, Alvarez RD, Bakkum-Gamez JN, Barroilhet L, Behbakht K, Berchuck A, Berek JS, Chen LM, Cristea M, DeRosa M, ElNaggar AC, Gershenson DM, Gray HJ, Hakam A, Jain A, Johnston C, Leath CA III, Liu J, Mahdi H, Matei D, McHale M, McLean K, O'Malley DM, Penson RT, Percac-Lima S, Ratner E, Remmenga SW, Sabbatini P, Werner TL, Zsiros E, Burns JL, Engh AM. Armstrong DK, et al. Among authors: berek js. J Natl Compr Canc Netw. 2019 Aug 1;17(8):896-909. doi: 10.6004/jnccn.2019.0039. J Natl Compr Canc Netw. 2019. PMID: 31390583
Progress in ovarian cancer.
Chen LM, Berek JS. Chen LM, et al. Among authors: berek js. Curr Opin Obstet Gynecol. 1998 Feb;10(1):51-5. doi: 10.1097/00001703-199802000-00010. Curr Opin Obstet Gynecol. 1998. PMID: 9484630 Review.
Detection of residual subclinical ovarian carcinoma after completion of adjuvant chemotherapy.
Nouriani M, Bahador A, Berek JS, Cheng JP, Chi DS, Cliby WA, Del Priore G, Dodson MK, Duggan BD, Gershenson DM, Lentz SE, Penson RT, Robinson WR, Rodriguez M, Roman LD, Yu MC, Zempolich K, Dubeau L. Nouriani M, et al. Among authors: berek js. Clin Cancer Res. 2004 Apr 15;10(8):2681-6. doi: 10.1158/1078-0432.ccr-0523-03. Clin Cancer Res. 2004. PMID: 15102671
Intraperitoneal chemotherapy for ovarian cancer.
Hamilton CA, Berek JS. Hamilton CA, et al. Among authors: berek js. Curr Opin Oncol. 2006 Sep;18(5):507-15. doi: 10.1097/01.cco.0000239892.21161.18. Curr Opin Oncol. 2006. PMID: 16894301 Review.
Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial.
Moore KN, Secord AA, Geller MA, Miller DS, Cloven N, Fleming GF, Wahner Hendrickson AE, Azodi M, DiSilvestro P, Oza AM, Cristea M, Berek JS, Chan JK, Rimel BJ, Matei DE, Li Y, Sun K, Luptakova K, Matulonis UA, Monk BJ. Moore KN, et al. Among authors: berek js. Lancet Oncol. 2019 May;20(5):636-648. doi: 10.1016/S1470-2045(19)30029-4. Epub 2019 Apr 1. Lancet Oncol. 2019. PMID: 30948273 Clinical Trial.
Characteristics of patients with small-volume residual ovarian cancer unresponsive to cisplatin-based ip chemotherapy: lessons learned from a Gynecologic Oncology Group phase II trial of ip cisplatin and recombinant alpha-interferon.
Markman M, Berek JS, Blessing JA, McGuire WP, Bell J, Homesley HD. Markman M, et al. Among authors: berek js. Gynecol Oncol. 1992 Apr;45(1):3-8. doi: 10.1016/0090-8258(92)90482-x. Gynecol Oncol. 1992. PMID: 1601332 Clinical Trial.
312 results